WazirX is set to resume operations after a 15-month hiatus following a $235 million cyberhack. The Singapore High Court approved a restructuring plan, promising users 85% of their balances by July 18, 2024, with the remainder over three years.
Inhibrx Biosciences shares surged nearly 76% in after-hours trading Thursday after the company reported positive Phase 2 trial results for its cancer drug Ozekibart.